Condition: NSCLC (Advanced Non-small Cell Lung Cancer) · Sponsor: BlossomHill Therapeutics
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.
This description comes directly from the study's public registry record.
Sponsor Contact · (858) 732-3880 · clinicaltrials@bhtherapeutics.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital - Arizona | Phoenix, Arizona, United States | Recruiting |
| The Regents of the University of California - Irvine, CA Campus | Irvine, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Stanford University Medical Center | Stanford, California, United States | Recruiting |
| Yale University - Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Recruiting |
| Sarah Cancer Research Institution - Florida Cancer Specialist | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06706076